Lyell Immunopharma Reports Leadership Changes
Ticker: LYEL · Form: 8-K · Filed: Sep 16, 2025 · CIK: 1806952
| Field | Detail |
|---|---|
| Company | Lyell Immunopharma, Inc. (LYEL) |
| Form Type | 8-K |
| Filed Date | Sep 16, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: leadership-change, executive-compensation, board-of-directors
TL;DR
Lyell Immunopharma shakes up leadership, check the new exec comp.
AI Summary
Lyell Immunopharma, Inc. filed an 8-K on September 16, 2025, reporting changes in its board of directors and certain officers, as well as updates to compensatory arrangements. The filing indicates a shift in the company's leadership structure and potential adjustments to executive compensation, effective September 15, 2025.
Why It Matters
Changes in a company's board and executive officers can signal strategic shifts or governance adjustments that may impact future performance and investor confidence.
Risk Assessment
Risk Level: medium — Leadership changes and adjustments to compensatory arrangements can introduce uncertainty regarding the company's strategic direction and operational stability.
Key Players & Entities
- Lyell Immunopharma, Inc. (company) — Registrant
- September 15, 2025 (date) — Effective date of reported changes
- September 16, 2025 (date) — Date of report filing
FAQ
What specific changes were made to the board of directors or officers?
The filing indicates changes in directors and certain officers, but the specific names and details of their departures or appointments are not provided in this excerpt.
What are the details of the compensatory arrangements mentioned?
The filing states that there are updates to compensatory arrangements of certain officers, but the specific details of these arrangements are not included in this provided text.
When were these changes effective?
The earliest event reported was effective as of September 15, 2025.
What is Lyell Immunopharma's primary business?
Lyell Immunopharma, Inc. is in the Pharmaceutical Preparations industry, SIC code 2834.
Where is Lyell Immunopharma's principal executive office located?
Lyell Immunopharma's principal executive offices are located at 201 Haskins Way, South San Francisco, California, 94080.
Filing Stats: 474 words · 2 min read · ~2 pages · Grade level 11.9 · Accepted 2025-09-16 16:22:46
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share LYEL Nasdaq Glo
Filing Documents
- d948282d8k.htm (8-K) — 23KB
- 0001193125-25-205020.txt ( ) — 130KB
- lyel-20250915.xsd (EX-101.SCH) — 3KB
- lyel-20250915_lab.xml (EX-101.LAB) — 17KB
- lyel-20250915_pre.xml (EX-101.PRE) — 11KB
- d948282d8k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Lyell Immunopharma, Inc. Date: September 16, 2025 By: /s/ Mark Meltz Mark Meltz General Counsel and Corporate Secretary